Compugen (CGEN) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Compugen (NASDAQ:CGEN) issued its earnings results on Monday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03, Morningstar.com reports.

Shares of Compugen stock opened at $3.34 on Wednesday. The company has a market cap of $178.50 million, a P/E ratio of -8.15 and a beta of 2.43. Compugen has a twelve month low of $2.00 and a twelve month high of $4.31.

CGEN has been the topic of several analyst reports. Oppenheimer set a $9.00 target price on shares of Compugen and gave the stock a “buy” rating in a research note on Tuesday, February 26th. Zacks Investment Research upgraded shares of Compugen from a “hold” rating to a “strong-buy” rating and set a $4.00 price objective on the stock in a research report on Friday, March 1st.

A number of institutional investors have recently modified their holdings of CGEN. Renaissance Technologies LLC lifted its position in Compugen by 8.2% during the third quarter. Renaissance Technologies LLC now owns 265,100 shares of the biotechnology company’s stock valued at $1,021,000 after purchasing an additional 20,200 shares during the period. Jane Street Group LLC bought a new position in Compugen during the third quarter valued at approximately $128,000. Morgan Stanley lifted its position in Compugen by 2.8% during the third quarter. Morgan Stanley now owns 998,173 shares of the biotechnology company’s stock valued at $3,843,000 after purchasing an additional 27,240 shares during the period. Taylor Frigon Capital Management LLC lifted its position in Compugen by 17.2% during the fourth quarter. Taylor Frigon Capital Management LLC now owns 690,262 shares of the biotechnology company’s stock valued at $1,498,000 after purchasing an additional 101,212 shares during the period. Finally, Defender Capital LLC. bought a new position in Compugen during the fourth quarter valued at approximately $630,000. Institutional investors own 25.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Compugen (CGEN) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS” was first published by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.wkrb13.com/2019/05/22/compugen-cgen-posts-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.

About Compugen

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Recommended Story: Recession

Earnings History for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.